BCL2L11 and hepatocellular carcinoma: Finally, we found that HCC cells treated with the EGFR inhibitor attenuated the 14-3-3σ-mediated enhancement of ERK1/2 phosphorylation and anoikis resistance, as well as normalizing the protein levels of Bcl2 and Bim (Figure 7).